When to stop GnRH analog therapy: The experience of the italian study group for physiopathology of puberty

T. Arrigo, M. Cisternino, F. Galluzzi, S. Bertelloni, A. M. Pasquino, F. Antoniazzi, P. Borrelli, G. Crisafulli, M. Wasniewska, F. De Luca

Research output: Contribution to journalArticlepeer-review

Abstract

Data reported in this study have been recently published elsewhere. The authors retrospectively analyzed the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP), who had been treated with the same therapy protocol (Decapeptyl Depot at the dose of 60 μg/kg i.m. every 28 days) for at least 2 years (since 7.0 ± 1.3 yr) and followed until puberty was completed and FH was reached. During the entire treatment period we observed: A) a decrease of height standard deviation scores (SDS) (from 1.5±1.7 to 0.9±1.3 SDS, p

Original languageEnglish
Pages (from-to)759-764
Number of pages6
JournalJournal of Pediatric Endocrinology and Metabolism
Volume13
Issue numberSUPPL. 1
Publication statusPublished - 2000

Keywords

  • Central precocious puberty
  • Final height
  • Gonadotropin releasing hormone agonists
  • Idiopathic early puberty

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'When to stop GnRH analog therapy: The experience of the italian study group for physiopathology of puberty'. Together they form a unique fingerprint.

Cite this